MRS and 11C-methionine PET/CT in the Diagnosis of Glioma
Not Applicable
Completed
- Conditions
- Glioma
- Interventions
- Other: tumors are confirmed by surgery and pathology
- Registration Number
- NCT03009318
- Lead Sponsor
- Huashan Hospital
- Brief Summary
MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI
- No surgery, chemotherapy or radiotherapy history
- All patients gave written informed consent.
Exclusion Criteria
- Patients with infratentorial Neoplasms
- Patients with enhancing supratentorial lesions
- Recurrent gliomas after surgery
- Primary gliomas with history of radiotherapy or chemotherapy
- History of malignant tumours at any body site
- Inability to give informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description MRS imaging and 11C-MET PET/CT tumors are confirmed by surgery and pathology Each patient underwent both MRS and MET PET before surgery.
- Primary Outcome Measures
Name Time Method Sensitivity of the combination of MRS and 11C-MET PET/CT 5 years
- Secondary Outcome Measures
Name Time Method The relationship between 11C-MET PET/CT results and molecular pathogeneses 5 years
Trial Locations
- Locations (1)
Huashan hospital, Fudan university
🇨🇳Shanghai, China